ArticleEBioMedicine2025
A generative vision-language model for holistic pathological assessment using preoperative imaging in hepatocellular carcinoma.
Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPathological evaluation of hepatocellular carcinoma (HCC) traditionally relies on surgical resection, posing risks of infection and complications while failing to provide comprehensive pathological insights preoperatively. This study aims to develop HepaPathGPT, which utilises preoperative imaging to deliver detailed pathological interpretations, enabling non-invasive, real-time pathological assessments for patients with HCC.
methodsA retrospective study of 1091 patients with HCC from 10 independent cohorts was used. SegFormer-b5 segmented tumour regions, and vision-language alignment mapped imaging features to pathology descriptions. We fine-tuned four pretrained frameworks using Low-Rank Adaptation (LoRA) to efficiently translate imaging features into structured histological reports, enabling real-time evaluation via an interactive interface.
findingsHepaPathGPT showed robust tumour segmentation (mean Intersection over Union: 0.883 ± 0.007, Dice: 0.934 ± 0.006) and an average accuracy of 0.697 ± 0.024 for six pathological markers in external validation (n = 109). For text generation, BLEU-4 and ROUGE-1 scores were 62.7 ± 1.7 and 84.2 ± 1.1. Five pathologists rated 92.5% and 87.4% of reports as acceptable for accuracy and completeness.
interpretationHepaPathGPT offers a approach for non-invasive pathological analysis in patients with HCC. This technology holds significant clinical value for decision-making in patients with HCC and promises scalability to other diseases in the future.
fundingNational Natural Science Foundation of China (82090053, 82090052, 12326618, 82272703, 82473201); Tsinghua University Initiative Scientific Research Program of Precision Medicine (2022ZLA007); CAMS Innovation Fund for Medical Sciences (2019-I2M-5-056); Elite Youth Project of Natural Science Foundation of Fujian Province (2023J06056); Science-Health Joint Medical Scientific Research Project of Chongqing (2023MSXM092).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.